 "Panacea Biotec dips as Q1 loss widens")
Shares of Panacea Biotec have tanked by 14% to Rs 137 on the National Stock Exchange (NSE) in an otherwise firm market after the company reported widening of net loss to Rs 36.90 crore in the quarter ended June 30 due to lower operational income.
The company had posted a net loss of Rs 23.54 crore for the corresponding period of the previous fiscal. It had reported a loss of Rs 31.39 crore in the March quarter, Panacea Biotec said in a filing to BSE.
The company's standalone total income from operations declined by 17% at Rs 125 crore in the quarter against Rs 151 crore in the same period a year ago.
At 12:51 PM, the stock was down 12% to Rs 140 on the NSE. A combined 219,038 shares changed hands on the counter on the NSE and BSE.
The company had posted a net loss of Rs 23.54 crore for the corresponding period of the previous fiscal. It had reported a loss of Rs 31.39 crore in the March quarter, Panacea Biotec said in a filing to BSE.
The company's standalone total income from operations declined by 17% at Rs 125 crore in the quarter against Rs 151 crore in the same period a year ago.
At 12:51 PM, the stock was down 12% to Rs 140 on the NSE. A combined 219,038 shares changed hands on the counter on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%